Sudan's Shift from Chloroquine to Artemisinin-based Combination Therapy
Author Information
Author(s): Malik EM, Mohamed TA, Elmardi KA, Mowien RM, Elhassan AH, Elamin SB, Mannan AA, Ahmed ES
Primary Institution: National Malaria Control Programme, Sudan
Hypothesis
How can Sudan effectively transition from chloroquine to artemisinin-based combination therapy for malaria treatment?
Conclusion
The implementation of the new malaria treatment policy in Sudan is hindered by drug availability, high costs, and limited manufacturers.
Supporting Evidence
- Chloroquine resistance has been documented in Sudan since the 1970s.
- 85.6% of severe malaria patients received chloroquine before hospitalization.
- ACTs have shown high efficacy with low failure rates in several studies.
Takeaway
Sudan is changing its malaria treatment from an old drug called chloroquine to a new combination therapy that works better, but it's hard because the new drugs are expensive and not always available.
Methodology
Data was collected from published and unpublished documents, including efficacy studies and official reports related to malaria treatment.
Limitations
The study is limited by the availability of drugs and the high costs associated with the new treatment.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website